Korean J Hematol.  2011 Jun;46(2):60-61. 10.5045/kjh.2011.46.2.60.

The next step for Burkitt lymphoma

• Cho B

• KMID: 1782765
• DOI: http://doi.org/10.5045/kjh.2011.46.2.60

Abstract

No abstract available.

MeSH Terms

Burkitt Lymphoma

Reference

1. de Leval L, Hasserjian RP. Diffuse large B-cell lymphomas and burkitt lymphoma. Hematol Oncol Clin North Am. 2009; 23:791–827. PMID: 19577170.

2. Kenkre VP, Stock W. Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma. 2009; 9(Suppl 3):S231–S238. PMID: 19778846.

3. Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol. 2002; 15:695–711. PMID: 12617871.

4. Park ES, Kim H, Lee JW, et al. Treatment outcomes in children with burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution. Korean J Hematol. 2011; 46:96–102.

5. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97:3370–3379. PMID: 11369626.

6. Poirel HA, Cairo MS, Heerema NA, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009; 23:323–331. PMID: 19020548.

7. Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. 2008. 4th ed. Lyon, France: IARC Press.

8. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010; 149:484–497. PMID: 20346013.